1
FOR IMMEDIATE RELEASE

COMPANY CONTACT:  CAROL COBURN
                  860.870.6112
                  BIO.PLEXUS@NET.NET.

Vernon, CT -- April 27 -- Bio-Plexus today announced a private placement
convertible debenture financing of up to $4,500,000. "This funding will help
enable us to capitalize on the exciting growth opportunities available today as
the market converts to safety medical products," said Richard L. Higgins,
president and CEO of Bio-Plexus.

"Right now only about 10% of all needle markets are safety devices. But we
expect these figures to change as additional states join Maryland, Tennessee and
California in passing legislation mandating the use of safety needles," Higgins
added. Bills continue to be introduced in other states, and Federal OSHA is also
considering more stringent regulations to ensure the use of safe needles.

Bio-Plexus, Inc. (NASDAQ: BPLX), is a designer, developer, manufacture, and
marketer of safety medical products and needles under the PUNCTUR-GUARD(R) and
DROP-IT(R) brand names. The company holds U.S. and international patents on
safety medical devices designed to reduce the incidence of accidental
needlesticks among healthcare workers. Accidental needlesticks number more than
one million per year in the United States and can result in the transmission of
deadly diseases including HIV and hepatitis.

NOTE: THIS PRESS RELEASE CONTAINS FORWARD-LOOKING STATEMENTS, WHICH ARE SUBJECT
TO RISKS AND UNCERTAINTIES. THE ACTUAL RESULTS MAY DIFFER MATERIALLY FROM THOSE
DESCRIBED IN ANY SUCH FORWARD-LOOKING STATEMENT AS A RESULT OF FACTORS DESCRIBED
FROM TIME TO TIME IN THE COMPANY'S PERIODIC REPORTS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION OR DISCUSSED IN OTHER PRESS RELEASES ISSUED BY THE
COMPANY.

####

1999